US 11,787,766 B2 · Compound having PD-L1 inhibitory activity, preparation method therefor and use thereof

Abstract

Provided are a compound for the prevention and treatment of diseases associated with PD-L1, a preparation method therefor and use thereof. Specifically, provided are the compound of formula I, the stereoisomer and the racemate thereof, or pharmaceutically acceptable salts thereof, and also provided is an application thereof in the preparation of a drug for the prevention and treatment of diseases associated with PD-L1.

Claims3

Dependent claims

A compound selected from the following group, or a stereoisomer, a racemate, or a pharmaceutically acceptable salt thereof,

No.
Structure of compound
6
9
17
20
22
24
26
27
28
30
33
35
37
39
41
42
43
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82

53 more elements

Dependencies are inferred from the claim text.

Facts

Application

16/639,949Filed 17 Aug 2018

Priority

CN 201710712191.818 Aug 2017

Published

US 2020/0392083 A117 Dec 2020

Granted

17 Oct 2023

Term ends

Not estimatedThe source records don’t support an estimate.

Classification42 codes

C07D 213/69
Oxygen or sulfur atoms: two or more oxygen atoms
A61K 31/137
Having aromatic rings , e.g. ketamine, nortriptyline: arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
A61K 31/165
Amides, e.g. hydroxamic acids: having aromatic rings, e.g. colchicine, atenolol, progabide
A61K 31/4155
1,2-Diazoles: non condensed and containing further heterocyclic rings

Compound having PD-L1 inhibitory activity, preparation method therefor and use thereof

Life of this patent

Compound having PD-L1 inhibitory activity, preparation method therefor and use thereof

Life of this patent

Abstract

Claims3